References
- Pellegrino P, Perrone V, Pozzi M, Carnovale C, Perrotta C, Clementi E, Radice S. The epidemiological profile of ASIA syndrome after HPV vaccination: an evaluation based on the vaccine adverse event reporting systems. Immunol Res. 2015;61(1–2):90–96. doi:10.1007/s12026-014-8567-3.
- Velikova T, Georgiev T. SARS-CoV-2 vaccines and autoimmune diseases amidst the COVID-19 crisis. Rheumatol Int. 2021;41:509–18. doi:10.1007/s00296-021-04792-9.
- Wendling D, Verhoeven F, Chouk M, Prati C. Can SARS-CoV-2 trigger reactive arthritis? Joint Bone Spine. 2020;88(1):105086. doi:10.1016/j.jbspin.2020.105086.
- Lyons-Weiler J. Pathogenic priming likely contributes to serious and critical illness and mortality in COVID-19 via autoimmunity. J Transl Autoimmun. 2020;3:100051. doi:10.1016/j.jtauto.2020.100051.
- Soriano A, Nesher G, Shoenfeld Y. Predicting post-vaccination autoimmunity: who might be at risk? Pharmacol Res. 2015;92:18–22. doi:10.1016/j.phrs.2014.08.002.
- Selmi C, Gershwin ME. Diagnosis and classification of reactive arthritis. Autoimmun Rev. 2014;13(4–5):546–49. doi:10.1016/j.autrev.2014.01.005.
- Gershwin LJ. Adverse reactions to vaccination: from anaphylaxis to autoimmunity. The veterinary clinics of North America. Small Anim Pract. 2018;48(2):279. doi:10.1016/j.cvsm.2017.10.005.
- Pellegrino P, Clementi E, Radice S. On vaccine’s adjuvants and autoimmunity: current evidence and future perspectives. Autoimmun Rev. 2015;14(10):880–88. doi:10.1016/j.autrev.2015.05.014.
- Segal Y, Shoenfeld Y. Vaccine-induced autoimmunity: the role of molecular mimicry and immune crossreaction. Cell Mol Immunol. 2018;15(6):586–94. doi:10.1038/cmi.2017.151.
- Moro PL, Haber P, McNeil MM. Challenges in evaluating post-licensure vaccine safety: observations from the centers for disease control and prevention. Expert Rev Vaccines. 2019;18(10):1091–101. doi:10.1080/14760584.2019.1676154.
- Pollard AJ, Bijker EM. A guide to vaccinology: from basic principles to new developments. Nat Rev Immunol. 2021;21(2):83–100. doi:10.1038/s41577-020-00479-7.
- Wu Z, Hu Y, Xu M, Chen Z, Yang W, Jiang Z, Li M, Jin H, Cui G, Chen P, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021. doi:10.1016/S1473-3099(20)30987-7.
- Bijlsma JW. EULAR December 2020 view points on SARS-CoV-2 vaccination in patients with RMDs. Ann Rheum Dis. 2021;80:411–12. doi:10.1136/annrheumdis-2020-219773.
- Poland GA, Ovsyannikova IG, Kennedy RB. Personalized vaccinology: a review. Vaccine. 2018;36(36):5350–57. doi:10.1016/j.vaccine.2017.07.062.
- Villanueva MT. Suppressing autoimmunity with mRNA vaccines. Nat Rev Drug Discov. 2021;20(2):99. doi:10.1038/d41573-021-00014-w.
- Flemming A. mRNA vaccine shows promise in autoimmunity. Nat Rev Immunol. 2021;21(2):72. doi:10.1038/s41577-021-00504-3.